Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies

被引：125
作者：
Dyall J. [1 ]
Gross R. [1 ]
Kindrachuk J. [2 ]
Johnson R.F. [3 ]
Olinger G.G., Jr. [4 ]
Hensley L.E. [1 ]
Frieman M.B. [5 ]
Jahrling P.B. [1 ,3 ]
机构：
[1] Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD
[2] Department of Medical Microbiology, University of Manitoba, Winnipeg, MN
[3] Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD
[4] University of Boston, Boston, MA
[5] Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, MD
来源：
Drugs | 2017年 / 77卷 / 18期
关键词：
D O I：
10.1007/s40265-017-0830-1
中图分类号：
学科分类号：
摘要：
No specific antivirals are currently available for two emerging infectious diseases, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature search was performed covering pathogenesis, clinical features and therapeutics, clinically developed drugs for repurposing and novel drug targets. This review presents current knowledge on the epidemiology, pathogenesis and clinical features of the SARS and MERS coronaviruses. The rationale for and outcomes with treatments used for SARS and MERS is discussed. The main focus of the review is on drug development and the potential that drugs approved for other indications provide for repurposing. The drugs we discuss belong to a wide range of different drug classes, such as cancer therapeutics, antipsychotics, and antimalarials. In addition to their activity against MERS and SARS coronaviruses, many of these approved drugs have broad-spectrum potential and have already been in clinical use for treating other viral infections. A wealth of knowledge is available for these drugs. However, the information in this review is not meant to guide clinical decisions, and any therapeutic described here should only be used in context of a clinical trial. Potential targets for novel antivirals and antibodies are discussed as well as lessons learned from treatment development for other RNA viruses. The article concludes with a discussion of the gaps in our knowledge and areas for future research on emerging coronaviruses. © 2017, Springer International Publishing AG.
引用
收藏
页码：1935 / 1966
页数：31
相关论文
共 164 条
[1]  
Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Et al., Bats are natural reservoirs of SARS-like coronaviruses, Science, 310, 5748, pp. 676-679, (2005)
[2]  
Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., Et al., Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats, Proc Natl Acad Sci USA, 102, 39, pp. 14040-14045, (2005)
[3]  
Revised U.S., surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases—United States and worldwide, December 2003, MMWR Morb Mortal Wkly Rep, 52, 49, pp. 1202-1206, (2003)
[4]  
Middle East respiratory syndrome coronavirus, (2017)
[5]  
Middle East respiratory syndrome coronavirus, (2017)
[6]  
Fehr A.R., Perlman S., Coronaviruses: an overview of their replication and pathogenesis, Methods Mol Biol, 1282, pp. 1-23, (2015)
[7]  
Pasternak A.O., Spaan W.J., Snijder E.J., Nidovirus transcription: how to make sense…?, J Gen Virol, 87, pp. 1403-1421, (2006)
[8]  
Perlman S., Netland J., Coronaviruses post-SARS: update on replication and pathogenesis, Nat Rev Microbiol., 7, 6, pp. 439-450, (2009)
[9]  
Eckerle I., Corman V.M., Muller M.A., Lenk M., Ulrich R.G., Drosten C., Replicative capacity of MERS coronavirus in livestock cell lines, Emerg Infect Dis., 20, 2, pp. 276-279, (2014)
[10]  
Memish Z.A., Mishra N., Olival K.J., Fagbo S.F., Kapoor V., Epstein J.H., Et al., Middle East respiratory syndrome coronavirus in bats, Saudi Arabia, Emerg Infect Dis., 19, 11, pp. 1819-1823, (2013)
12345678910